Studies side effects of fast high-dose radiation inside the womb for cervical cancer
Tracks side effects of fast radiation in adults with locally advanced cervical cancer.
Plain-language title generated from the registry record
Registry title: Evaluation of Ultraaccelerated High Dose Rate Intrauterine Interventional Radiotherapy
Key facts
- Where
- Rome, ItalySee the site
Where in Italy
- Fondazione Policlinico Universitario A. Gemelli IRCCSRome, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Trial code
- NCT06398938
- Record updated
- 15 August 2025
- Original description
To evaluate the degree of acute and long-term intestinal, urinary and vaginal toxicity, and the impact on sexual activity of an accelerated fractionation of high dose rate interventional radiotherapy (IRT-HDR) in patients with locally advanced cervical cancer (IB2 - VA, N+/-).Read full original descriptionShow less
EROS 3 Study Evaluation of Ultraaccelerated High Dose Rate Intrauterine Interventional Radiotherapy Brachytherapy in Terms of Overall Toxicity and Sexual Activity
To evaluate the degree of acute and long-term intestinal, urinary and vaginal toxicity, and the impact on sexual activity of an accelerated fractionation of high dose rate interventional radiotherapy (IRT-HDR) in patients with locally advanced cervical cancer (IB2 - VA, N+/-).
Inclusion: Age ≥18 years; ECOG 0-2; Histological diagnosis of squamous carcinoma and/or adenocarcinoma of the uterine cervix; FIGO IB2 Stadium - IVA (staging 20018); No contraindications to performing MRI of the pelvis; Informed consent.
Exclusion: Previous radiation treatment in the region of interest; Previous cancer in the last 10 years; Presence of pathologies that contraindicate radiotherapy treatment (genetic syndromes of hyper-radiosensitivity, ulcerative colitis, diverticulitis in the acute phase, severe diverticulosis, chronic pelvic inflammation); Presence of internal diseases that contraindicate chemotherapy or radio-chemotherapy treatment (severe liver disease, heart disease, renal failure, etc.); Any significant medical condition that in the opinion of the investigator may interfere with the patient's optimal participation in the study; Age <18 years; PS >2; Presence of distant metastases in sites other than the pelvic lymph nodes.